Given that the PI3K-AKT pathway leads to the activation of mTOR, and the mTOR pathway is disrupted in cancer, it is interesting for us to discuss the drug Rapamycin in the context of these and other pathways, as it holds elucidations on our theory. The gene discussed is AKT1; the disease is cancer.